Eli Lilly Earnings: Another Blowout, Another Guidance Hike

April 30, 2026

Eli Lilly Just Raised the Bar. Again.

Eli Lilly LLY didn't just beat earnings expectations for the first quarter. It obliterated them, delivering a performance so strong it forced the company to hike its full-year outlook for a second time. The story, as it has been for the past year, is written in the sales figures for its twin GLP-1 titans: Mounjaro and Zepbound.

The takeaway for investors? The GLP-1 gold rush is far from over, and Lilly is still the undisputed leader in capturing its value. For traders, the question shifts from "Is demand sustainable?" to "How high can this go before execution or competition becomes a real headwind?"

The Numbers That Mattered

Let's cut through the noise. Here’s what moved the market this morning:

Adjusted EPS: $8.55 vs. $6.66 expected. That’s a 28% beat.
Revenue: $19.80 billion vs. $17.62 billion expected. A 12% surprise.
Full-Year 2026 Guidance: Sales outlook raised by $2 billion to $82-85 billion. EPS guidance lifted to $35.50-$37, up from $33.50-$35.

Shares surged over 5% premarket on the print. When you beat on the top and bottom line *and* raise guidance, the market rewards you. It’s that simple.

The Engine Room: Mounjaro & Zepbound Fire on All Cylinders

Drill down, and the dominance is staggering. This is a two-drug company, and both drugs are performing at a level that’s redefining "blockbuster."

Mounjaro’s worldwide revenue hit $8.66 billion, up 125% year-over-year and well ahead of the $7.26 billion analysts anticipated. Zepbound, still in its relative infancy, posted $4.16 billion in U.S. sales, up 80% and beating expectations of $4.04 billion.

Here’s the critical context for the market: this explosive growth came despite lower realized prices. U.S. revenue was driven by a staggering 49% increase in volume. CEO David Ricks’s bet is clear: sacrifice some price to drive massive adoption and cement market leadership. It’s a classic land-grab strategy, and it’s working. Lilly now commands over 60% of the combined U.S. obesity and diabetes GLP-1 market, leaving rival Novo Nordisk with just under 40%.

The New Front in the GLP-1 War: The Pill Race

All eyes are now on the next battlefield: oral medications. Lilly’s newly approved pill, Foundayo, launched this quarter, setting the stage for a direct face-off with Novo’s Wegovy pill, which had a three-month head start.

So, who wins the pill war? It’s too early to call. Early prescription data suggests Foundayo’s launch has been "modest," according to analyst notes. The earnings call will be dominated by questions on Foundayo’s trajectory. Can it replicate the injectable frenzy? The pill format is a key to unlocking a broader patient pool—those wary of needles—so the stakes are enormous.

The narrative for the next few quarters will hinge on prescription trend data for this new entrant. For now, the injectable cash cows are more than covering the bet.

Market Implications: The Good and The Prickly

For investors, the bull case is reinforced. Lilly is executing flawlessly in the hottest sector in pharma. The guidance hike signals management's supreme confidence in demand through 2026. Ricks’s projection of global GLP-1 users growing from 20 million to 30 million by year-end underscores the runway.

But traders need to watch the prickly edges. The company explicitly called out pricing pressure ahead, pointing to policy changes and the natural price erosion that comes with volume-based rebates. Can volume growth continue to outpace price declines indefinitely? That’s the multi-billion dollar question.

Furthermore, with a market cap now soaring past $700 billion, expectations are astronomically high. The stock trades on perfection. Any stumble in volume growth, manufacturing hiccups, or clinical setbacks for the expansive pipeline could trigger a sharp re-rating.

Today’s report confirms the trend: Eli Lilly remains the king of the GLP-1 hill. But in this market, being king means you have the most to lose. Every subsequent quarter is a test of whether it can keep defying gravity.